Merck KGaA, Darmstadt, Germany: all 522 studies

Page 4 of 6. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated SyndromeCompletedNCT00287079Phase 3Results posted
• Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis PatientsCompletedNCT00262314Results posted
• Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®CompletedNCT00256126Phase 4Results posted
• Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF)CompletedNCT00249834Phase 4Results posted
• Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational AgeCompletedNCT00249821Phase 3Results posted
• A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic TherapiesCompletedNCT00249808Phase 4Results posted
• Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric CancerCompletedNCT00215644Phase 2Results posted
• Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory DysfunctionCompletedNCT00213148Phase 2Results posted
• A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)CompletedNCT00213135Phase 3Results posted
• Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)CompletedNCT00157209Phase 2Results posted
• Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III DiseaseCompletedNCT00157196Phase 2Results posted
• Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)CompletedNCT00154102Phase 3Results posted
• Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)CompletedNCT00148798Phase 3Results posted
• Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid ArthritisCompletedNCT00146640Phase 3Results posted
• Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)CompletedNCT00125034Phase 2Results posted
• Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)CompletedNCT00122460Phase 3Results posted
• Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung CancerCompletedNCT00111839Phase 2Results posted
• Rebif New Formulation (RNF) in Relapsing Forms of Multiple SclerosisCompletedNCT00110396Phase 3Results posted
• Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone DeficiencyCompletedNCT00109733Phase 3Results posted
• Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated DyskinesiaCompletedNCT00105521Phase 3Results posted
• Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated DyskinesiaCompletedNCT00105508Phase 3Results posted
• Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)CompletedNCT00093964Phase 2Results posted
• Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) PatientsCompletedNCT00082628Phase 3Results posted
• Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisCompletedNCT00078338Phase 4Results posted
• To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy ParticipantsCompletedNCT07279233Phase 1
• An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian OriginCompletedNCT07269327Phase 1
• To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male ParticipantsCompletedNCT07259330Phase 1
• Evaluate the Effects of Famotidine or Rabeprazole on the PK of NirogacestatCompletedNCT07171619Phase 1
• A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)Active, not recruitingNCT07170644Phase 2
• A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male ParticipantsCompletedNCT07097259Phase 1
• Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid TumorsActive, not recruitingNCT06806046Phase 1
• Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)WithdrawnNCT06719973Phase 1
• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Phase 1/2
• A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy ParticipantsCompletedNCT06589726Phase 1
• Effect of Renal Impairment on Enpatoran PharmacokineticsCompletedNCT06589713Phase 1
• Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy ParticipantsSuspendedNCT06577337Phase 1
• M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)TerminatedNCT06509906Phase 1
• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)CompletedNCT06433219Phase 2
• Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)WithdrawnNCT06424717Phase 2
• M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Active, not recruitingNCT06421935Phase 1
• JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment StudyCompletedNCT06412848
• Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)CompletedNCT06308263Phase 1
• Concor® Bioequivalence Study in Chinese Participants (Darmstadt-Nantong)CompletedNCT05930808Phase 1
• Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)CompletedNCT05882734Phase 1/2
• Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)Active, not recruitingNCT05797740
• The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)Active, not recruitingNCT05540327Phase 2
• Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)Active, not recruitingNCT05464030Phase 1
• GXR RM China BE Study (Darmstadt - Jiangsu)CompletedNCT05463094Phase 1
• Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)CompletedNCT05396833Phase 1
• Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy ParticipantsCompletedNCT05245396Phase 1
• BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites)CompletedNCT05174000Phase 1
• Enpatoran Human Mass Balance and Absolute Bioavailability StudyCompletedNCT05110027Phase 1
• Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminatedNCT05081180Phase 1
• Next-Gen MS: Feed-forward PRO Data for MS ResearchTerminatedNCT04907305
• Pergoveris FD and Liquid China BE StudyCompletedNCT04899193Phase 1
• Study of M5049 in Healthy Japanese and Caucasian ParticipantsCompletedNCT04880213Phase 1
• The MS-LINK™ Outcomes StudyCompletedNCT04735406
• Effect of Food on Peposertib PKCompletedNCT04702698Phase 1
• Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy ParticipantsCompletedNCT04697511Phase 1
• M1231 in Participants With Solid TumorsCompletedNCT04695847Phase 1
• Study of M4344 in Combination With NiraparibWithdrawnNCT04655183Phase 1/2
• Study of M5049 in CLE and SLE ParticipantsCompletedNCT04647708Phase 1
• Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial TabletsCompletedNCT04314024Phase 1
• Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)Active, not recruitingNCT04170153Phase 1
• Deflox Tablets Bioequivalence (BE) TrialCompletedNCT04132583Phase 1
• Effect of Meal Composition and Timing on Evobrutinib BioavailabilityCompletedNCT03934502Phase 1
• Avelumab Program Rollover StudyActive, not recruitingNCT03815643Phase 3
• Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-EvobrutinibCompletedNCT03725072Phase 1
• Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy ParticipantsCompletedNCT03676322Phase 1
• Retrospective Study to Estimate the Current Status of Patients With Non-Obstructive coroNary Artery DiseaseCompletedNCT03584321
• Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)CompletedNCT03583346Phase 1
• Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)CompletedNCT03436394Phase 1
• M7583 Relative Bioavailability of Tablet Compared to Powder-in-capsuleCompletedNCT03297983Phase 1
• Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and LymphocytesCompletedNCT03284970
• First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy VolunteersCompletedNCT03224702Phase 1
• Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)TerminatedNCT03116971Phase 1
• Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)Approved for marketingNCT03089658
• Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)CompletedNCT02921035
• A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) TreatmentCompletedNCT02889380
• A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian StimulationCompletedNCT02607293
• MSC2364447C Phase 1b in Systemic Lupus ErythematosusCompletedNCT02537028Phase 1
• Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)TerminatedNCT02394782
• Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic LeukemiaCompletedNCT02316197Phase 1
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in ColumbiaCompletedNCT02208076
• M6620 First in Human StudyCompletedNCT02157792Phase 1
• A Phase 1 TH-302 Mass Balance TrialCompletedNCT02076230Phase 1
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Middle EastCompletedNCT02015286
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ (ECOS Taiwan, Indonesia, Singapore)CompletedNCT02015273
• First-in-Human Dose Escalation Trial in Subjects With Advanced MalignanciesCompletedNCT01971515Phase 1
• Adherence Trial With MS LifeLines ® ServicesTerminatedNCT01905527
• A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile WomenCompletedNCT01735422Phase 2
• Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung CancerWithdrawnNCT01731587Phase 1
• Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) PatientsCompletedNCT01601119
• An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection DeviceCompletedNCT01601080
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in ArgentinaCompletedNCT01582334
• Cilengitide Imaging Trial in GlioblastomaTerminatedNCT01558687Phase 1
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in MexicoCompletedNCT01555528
• Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin TabletsWithdrawnNCT01510522Phase 4
• Pharmacokinetics in Subjects With Renal ImpairmentCompletedNCT01504165Phase 1
• A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical PracticeCompletedNCT01460745

← Merck KGaA, Darmstadt, Germany overview and focus areas